• 我要登录|
  • 免费注册
    |
  • 我的丁香通
    • 企业机构:
    • 成为企业机构
    • 个人用户:
    • 个人中心
  • 移动端
    移动端
丁香通 logo丁香实验_LOGO
搜实验

    大家都在搜

      大家都在搜

        0 人通过求购买到了急需的产品
        免费发布求购
        发布求购
        点赞
        收藏
        wx-share
        分享

        Determination of HIV-1 Chemokine Coreceptor Tropism Using Transduced Human Osteosarcoma (HOS) Cells

        互联网

        664
        CD4 was identified in 1984 as the receptor for HIV-1 (1 ,2 ). However, it was soon apparent that a second receptor was necessary for HIV-1 infection of CD4+ cells. This coreceptor was first identified by Berger and colleagues who showed that fusion and entry of T-cell line-adapted strains of HIV-1 into CD4+ cells were mediated by a member of the seven transmembrane chemokine receptor family (3 ). This protein was initially termed “fusin” and later found to be the α-chemokine receptor CXCR4. Subsequent reports by several laboratories rapidly identified a β-chemokine receptor, CCR5, that mediated entry of macrophage tropic HIV-1 isolates into CD4+ cells (4 8 ). Since these initial reports, our understanding of HIV-1 cell entry has continued to evolve. It now seems clear that primary HIV-1 strains with a nonsyncytium-inducing pheno-type (in MT2 cells) utilize the CCR5 coreceptor and are designated “R5,” whereas syncytium-inducing viruses preferentially utilize CXCR4, but may be dual tropic and are designated either “X4” or X4R5, respectively (9 ,10 ). Some viruses also appear to be able to utilize chemokine receptors CCR2B and CCR3 (7 10 ). In addition, the role of chemokine coreceptors in the pathophysiology of HIV-1 infection and disease progression is just beginning to be understood. Individuals who are homozygous for a 32-bp deletion in the CCR5 gene are only rarely found to be HIV-1-infected, and the heterozygous CCR5/Δccr5 genotype has been associated with a survival advantage against HIV-1 disease progression (11 14 ).
        ad image
        提问
        扫一扫
        丁香实验小程序二维码
        实验小助手
        丁香实验公众号二维码
        扫码领资料
        反馈
        TOP
        打开小程序